Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nikethamide→

Nikethamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59-26-7
Molecular formula
C10H14N2O
Molecular weight
178.23 g/mol
Drug class
Respiratory analepticnon-selective central nervous system stimulant (historical)
Mechanism of action
Produces central nervous system and respiratory stimulation through non-selective excitatory actions on brainstem and higher neural pathways. Its molecular mechanism is not sufficiently selective or fully defined.
Indications / reported uses
  • Historically used as a respiratory stimulant in respiratory depression and poisoning; it is not a routine contemporary treatment because safer, more effective supportive and specific treatments are available.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8057823/ · https://jamanetwork.com/journals/jama/article-abstract/666253 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nikethamide Environmental Risk Assessment (ERA) (the Nikethamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.